

Ugo C. Nzeako, MD, MPH

PUBLICATIONS

1. **Nzeako UC**, Longhurst HJ. Many faces of angioedema: Focus on diagnosis and management of abdominal manifestations of hereditary angioedema. *Eur J Gastroenterol Hepatol* 2012; 24: 353-61.
2. Longhurst HJ, **Nzeako UC**. Diagnosis and treatment of hereditary angioedema attacks in the emergency department and hospital: A brief review. *Br J Hosp Med* 2012; 73: 148-54.
3. **Nzeako UC**. Diagnosis and management of angioedema with abdominal involvement: A gastroenterology perspective. *World J Gastroenterol* 2010; 16: 4913-21.
4. Slijkhuis WA, Stadheim L, Hassoun ZM, **Nzeako UC**, Kremers WK, Talwalker JA, Gores GJ. Octreotide therapy for advanced hepatocellular carcinoma. *Journal of Clinical Gastroenterology* 2005; 39: 333-8.
5. **Nzeako UC**, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. *Alimentary Pharmacology and Therapeutics* 2002; 16: 1309-16.
6. Frigas E, **Nzeako UC**. Angioedema: pathogenesis, differential diagnosis, and treatment. *Clinical Reviews in Allergy and Immunology* 2002; 23: 217-31.
7. **Nzeako UC**, Frigas E, Tremaine WJ. Hereditary angioedema as a cause of transient abdominal pain. *Journal of Clinical Gastroenterology* 2002; 34: 57-61.
8. **Nzeako UC**, Gores GJ. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors [Letter]. *Cancer* 2002; 94: 1903-4.
9. **Nzeako UC**, Murray JA, Chari ST. Role of tube design and selection in the occurrence of gastric lesser curvature ulceration by percutaneous gastrostomy tubes: an issue for adult patients? *Digestive Diseases & Sciences* 2001; 46: 1827-32.
10. **Nzeako UC**, Sobin LH. Intestinal involvement by metastatic malignant melanoma [Letter]. *Gastrointestinal Endoscopy* 2001; 53: 403.
11. **Nzeako UC**. Male gynaecomastia [Letter]. *Consultant* 2001; 41: 23.
12. **Nzeako UC**, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. *Archives of Internal Medicine* 2001; 161: 2417-29.
13. Murakata LA, Ishak KG, **Nzeako UC**. Clear cell carcinoma of the liver: A comparative immunohistochemical study with renal clear cell carcinoma. *Modern Pathology* 2000; 13: 874-81.
14. **Nzeako UC**, Schneiderman H. Cutaneous amebiasis complicating intestinal amebiasis. *Consultant* 1999; 39: 1798-1802.
15. **Nzeako UC**, Schneiderman H. Calabar swelling of Loasis. *Consultant* 1998; 38: 153-8.
16. **Nzeako UC**, Schneiderman H. Nails in atopic dermatitis. *Consultant* 1997; 37: 364-7.

17. **Nzeako UC**, Schneiderman H. Chancroid. *Consultant* 1997; 37: 1001-5.
18. **Nzeako UC**, Schneiderman H. Skin manifestations of porphyrias. *Consultant* 1997; 37: 2169-76.
19. Schneiderman H, **Nzeako UC**. Ranula. *Consultant* 1996; 36: 311-2.
20. Schneiderman H, **Nzeako UC**. Perianal herpes lesions in HIV. *Consultant* 1996; 36: 1243-7.
21. **Nzeako UC**, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and non-cirrhotic livers: a clinico-histopathologic study of 804 North American patients. *American Journal of Clinical Pathology* 1996; 105: 65-75.
22. **Nzeako UC**, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. *American Journal of Gastroenterology* 1996; 91: 879-84.
23. Elsayed A, Albahra M, **Nzeako UC**, Sobin L. Malignant melanoma in the small intestine: a study of 103 patients. *American Journal of Gastroenterology* 1996; 91: 1001-6.
24. Carr NJ, Monihan JM, **Nzeako UC**, Murakata LA, Sobin LH. Expression of proliferating cell nuclear antigen in hyperplastic polyps, adenomas and inflammatory cloacogenic polyps of the large intestine. *Journal of Clinical Pathology* 1995; 48: 46-52.
25. Carr NJ, Albahra MA, **Nzeako UC**, Sobin LH. Proliferating cell nuclear antigen (PCNA) immunoexpression in hyperplastic polyps and adenomas of the appendix. *International Journal of Surgical Pathology* 1995; 2: 275-80.
26. **Nzeako UC**, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. *Cancer* 1995; 76: 579-88.
27. **Nzeako UC**. Etiologic factors and clinical presentation of hepatocellular carcinoma [Letter]. *Cancer* 1995; 76: 915.
28. **Nzeako UC**, Goodman ZD, Ishak KG. Association of hepatocellular carcinoma in North American patients with extrahepatic primary malignancies. *Cancer* 1994; 74: 2765-71.